Merck (MRK) and Sirna (RNAI) Merck Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of Sirna by Merck
More News related to MRK
- New Merck Begins Operations
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Merck and Schering-Plough to Complete Merger Today
- Wells Fargo Downgrades GTx, Inc. (GTXI) to Market Perform; Lack of Near-Term Catalyst Keep Shares Range Bound
- Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability 50 Index
More News related to RNAI
- 52-Week Highs of Note
- Merck (MRK) and Sirna (RNAI) Merck Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of Sirna by Merck
- Sirna Therapeutics (RNAI) Reports a Q3 Loss
- HealthCor Management Sends New Letter to ICOS (ICOS) Opposing Eli Lilly Takeover
- Rodman & Renshaw Bullish on Bioenvision (BIVN), Says Stock Does Not Reflect Clofarabine or Buyout
Merck & Co., Inc. (NYSE: MRK) and Sirna Therapeutics, Inc. (NASDAQ: RNAI) announced that the federal regulatory antitrust waiting period expired for Merck & Co.'s approximately $1.1 billion acquisition of Sirna Therapeutics. On Oct. 30, 2006, Merck entered into a definitive agreement to acquire Sirna for $13 per share in an all-cash transaction.
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration, hepatitis C, dermatology, asthma, respiratory syncytial virus and Huntington's disease
Related Categories
Mergers and AcquisitionsStocks Mentioned
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
